预约演示
更新于：2026-09-10
Doxycycline
多西环素
更新于：2026-09-10
概要
基本信息
简介Doxycycline是一种广谱抗生素，常用于治疗多种细菌感染症，如痤疮、肺炎和腹泻等疾病。它属于四环素类抗生素，通过抑制细菌蛋白质的合成来发挥作用。Doxycycline以口服或注射剂型供应，吸收迅速且耐受性良好。它可能会引起一些副作用，如恶心、呕吐和头晕等。作为研究和开发研究人员，需要注意的是，Doxycycline正在被研究用于治疗其他疾病，例如痛风和自闭症等疾病，但仍需进一步研究来确定其效果。 |
药物类型 小分子化药 |
别名 Doxycycline、Doxycycline (USP)、Doxycycline hydrate + [7] |
作用方式 抑制剂 |
作用机制 30S subunit抑制剂(30S核糖体亚基抑制剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1967-12-06), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H26N2O9 |
InChIKeyXQTWDDCIUJNLTR-CVHRZJFOSA-N |
CAS号17086-28-1 |
关联
153
项与 多西环素 相关的临床试验NCT06349122
Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth: A Multicentre, Randomized Study (AUTOP 2)
NCT07361926
Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women
NCT06452394
NEODOXy: Targeting Cancer Stem Cells With NEOadjuvant DOXYcycline in Patients With Early Estrogen Receptor Positive / Human Epidermal Growth Factor Receptor 2- Negative Breast Cancer. A Prospective, Multicenter, Single Arm, Open Label Phase II Trial
100 项与 多西环素 相关的临床结果
登录后查看更多信息
100 项与 多西环素 相关的转化医学
登录后查看更多信息
100 项与 多西环素 相关的专利（医药）
登录后查看更多信息
24,753
项与 多西环素 相关的文献（医药）2027-01-01BIOMATERIALS
Synthetic polypeptide adjuvant-antibiotic combination eradicates polymicrobial assemblies, dormant bacteria and bacterial biofilm
Article
作者: Older, Ethan ; Li, Jie ; Hossain, Md Waliullah ; Barman, Swagatam ; Bansidhar, Aiswarya Chandrasseril ; Decho, Alan W ; Tang, Chuanbing
In this work, we explore the potency of poly(D-peptide) (D-PP) in combination with diverse classes of antibiotics to address multidrug-resistant (MDR) Gram-negative superbugs, including their mature biofilms, polymicrobial assemblies, and dormant subpopulations, which are among complex challenging targets. The polypeptide adjuvant displayed significant antibiotic potentiation, resulting in a moderate to rapid bactericidal activity against the Gram-negative pathogens in their planktonic stage. The adjuvant and its combination restored susceptibility in dormant bacterial subpopulations. In polymicrobial settings, these combinations were able to reduce both Gram-negative and Gram-positive bacterial species, unlike individual antibiotic exposure. Importantly, one of the lead combinations (D-PP-rifampicin) resulted in moderate biofilm eradication of P. aeruginosa. Transcriptomic analysis demonstrated the differentially expressed genes (DEGs) involved in membrane integrity, stress response, and transport systems. Together with our previous mechanistic findings, this further confirmed that bacterial membrane perturbation is caused by the adjuvant. Such perturbation facilitated antibiotic accumulation within microbial cells. Furthermore, polypeptide reduces the bacterial resistance development towards doxycycline and rifampicin, unlike polymyxin B. Taken together, these findings exhibit that membrane-active polypeptide adjuvants can enhance antibiotic efficacy across diverse bacterial states and environments, providing a promising strategy to combat persistent and multidrug-resistant infections.
2026-12-31European Clinical Respiratory Journal
Lung abscess as an adverse effect of Risankizumab
Article
作者: Kazi, Zarif ; Donenfeld, Thai ; Pascal, William ; Jesin, Stuart ; Clements, Kevin ; Lewis, Toni-Ann ; Ghimire, Samir
Background:
Risankizumab is used for prolongated duration by patients, necessitating further research to characterize the infectious risks involved.
Case Presentation:
A 30-year-old man on Risankizumab for psoriasis and alopecia presented with pleuritic chest pain, cough, hemoptysis, fever, and myalgias. Initial computed tomography (CT) scan showed a 4.9 × 7.7 × 6.1 cm irregular cavitary lesion in the medial right lower lobe with thickened walls and surrounding ground-glass opacification. Tuberculosis was ruled out with 3 negative acid-fast bacilli (AFB) samples and 2 negative samples for Mycobacterium tuberculosis and rifampin resistance assay (Xpert MTB/RIF). Empiric antibiotic therapy was initiated, though the patient remained persistently febrile and tachycardic despite reported symptomatic improvement. A repeat CT scan showed compression atelectasis of the right middle and lower lobes, and a large right pleural effusion with multiple air-fluid levels. The patient underwent a video-assisted thoracoscopic surgery (VATS) decortication. Pleural fluid culture grew methicillin-resistant Staphylococcus aureus, and sputum AFB culture from admission grew Mycobacterium avium three weeks after collection. The patient ultimately completed two weeks of oral doxycycline.
Conclusion:
Given the lack of notable risk factors for lung abscess, this case suggests a possible association with Risankizumab, which may have contributed to immunosuppression.
2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Comparative efficacy and safety of oral azithromycin versus doxycycline in moderate-to-severe Acne vulgaris: a systematic review and meta-analysis
Review
作者: Yaqoob, Raafay ; Ali Akbar, Makhzan ; Ali, Umair ; Mahin, Fakhar e ; Maryam, Zoona ; Fazal, Menahil ; Ahmed, Abu-Bakr ; Aminpoor, Hasibullah ; Silva Correia, Joao Victor ; Murtaza, Meer ; Batool, Asia ; Abbas, Muhammad Sharjeel ; Khattak, Muhammad Huzaifa
BACKGROUND:
Acne vulgaris is a chronic inflammatory disease and is one of the leading causes of dermatological morbidities among young adults. Doxycycline is widely recommended as first-line therapy for moderate to severe acne; however, its use is limited.
OBJECTIVE:
To systematically compare the efficacy and safety of oral azithromycin pulse therapy versus doxycycline in patients with moderate to severe acne vulgaris.
METHODS:
This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive literature search on different databases was performed. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models based on heterogeneity.
RESULTS:
A total of 23 comparative studies comprising 2,769 patients were included. Pooled analysis demonstrated a statistically significant improvement in global acne severity favoring azithromycin (GAGS reduction: MD 1.81; 95% CI 1.28-2.34; I2 = 0%). Azithromycin achieved a significantly greater reduction in non-inflammatory lesion counts (MD -7.56; 95% CI -14.33 to -0.79). No significant differences were observed in inflammatory lesion reduction (MD 1.08; 95% CI -0.03 to 2.18).
CONCLUSION:
Oral azithromycin pulse therapy appears to have similar efficacy, better tolerability, and fewer side effects as compared to doxycycline.
100 项与 多西环素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 澳大利亚 | 2008-06-24 | |
| 细菌感染 | 澳大利亚 | 2008-06-24 | |
| 革兰氏阴性菌感染 | 澳大利亚 | 2008-06-24 | |
| 疟疾 | 澳大利亚 | 2008-06-24 | |
| 玫瑰痤疮 | 美国 | 2006-05-26 | |
| 感染 | 美国 | 1967-12-06 | |
| 感染 | 美国 | 1967-12-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特应性皮炎 | 临床2期 | 美国 | 2023-04-25 | |
| 神经纤维瘤病 | 临床2期 | - | - | |
| 晚期恶性实体瘤 | 临床1期 | 中国 | 2019-07-04 | |
| 晚期恶性实体瘤 | 临床1期 | 中国 | 2019-07-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 240 | PrEP discontinuation intervention+Injectable PrEP+Offering of STI PEP+Offering of on-demand oral PrEP | 網顧網夢齋鏇遞遞獵構 = 衊遞醖糧遞醖窪簾築網 齋簾蓋願蓋顧蓋積衊壓 (網鹽襯齋獵鬱製齋壓憲, 遞獵鹹鏇廠製襯襯蓋繭 ~ 築遞淵蓋艱鹹膚獵膚顧) 更多 | - | 2026-04-01 | ||
临床2期 | 7 | (Arm A (Metformin Hydrochloride)) | 觸餘顧齋餘網範簾餘觸(製齋網餘廠餘積繭窪鹽) = 窪積鏇蓋網糧衊糧製選 膚衊鏇選醖獵衊憲襯鹽 (觸餘鹽觸蓋壓襯鹹鹽願, 齋艱簾餘選選範遞遞獵 ~ 鏇鏇積蓋積觸鹽獵鹹壓) 更多 | - | 2026-01-29 | ||
(Arm B (Doxycycline)) | 觸餘顧齋餘網範簾餘觸(製齋網餘廠餘積繭窪鹽) = 鹽鏇築觸獵製憲製願壓 膚衊鏇選醖獵衊憲襯鹽 (觸餘鹽觸蓋壓襯鹹鹽願, 製廠選廠壓餘憲鏇夢獵 ~ 簾蓋憲構蓋顧鹽憲壓膚) 更多 | ||||||
临床4期 | 94 | cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+amoxicillin-clavulanate+linezolid+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental)) | 醖鹹鹽製鹹憲繭襯鹽鑰 = 範網廠遞鑰齋觸觸鑰積 夢鏇選憲齋簾鹽艱鏇繭 (願衊衊鹽憲鏇醖鑰壓範, 獵選繭鑰簾範憲網糧顧 ~ 觸鹽壓選蓋積積遞繭遞) 更多 | - | 2025-08-26 | ||
醖鹹鹽製鹹憲繭襯鹽鑰 = 艱網願鑰遞選鹽鏇淵憲 夢鏇選憲齋簾鹽艱鏇繭 (願衊衊鹽憲鏇醖鑰壓範, 壓襯願範壓獵築築襯艱 ~ 簾衊膚鑰獵繭鑰鏇願壓) 更多 | |||||||
N/A | 100 | 築觸餘壓壓構簾壓繭膚(選膚壓繭築選積選艱蓋) = 艱選襯觸積醖醖鹹憲糧 壓顧繭艱製膚鬱範願齋 (鏇糧窪衊鹹夢網鹽齋繭 ) 更多 | 不佳 | 2023-07-10 | |||
Iodopovidone | 築觸餘壓壓構簾壓繭膚(選膚壓繭築選積選艱蓋) = 構醖艱範簾艱憲糧鑰製 壓顧繭艱製膚鬱範願齋 (鏇糧窪衊鹹夢網鹽齋繭 ) 更多 | ||||||
临床4期 | 198 | Combination therapy | 窪鏇鑰鹽夢獵顧窪餘窪(遞憲鏇醖鹹淵淵淵淵遞) = 簾鏇鹹築積憲蓋糧製鏇 願襯鏇築壓夢廠鏇鹽糧 (醖網壓遞蓋鏇淵構鬱獵 ) 更多 | - | 2023-07-03 | ||
临床2期 | 44 | 構襯繭獵醖醖憲糧積衊(衊製壓糧願夢憲艱鬱膚) = 鏇鏇鏇鹹顧鹽鬱鹽廠鹽 蓋憲廠壓壓蓋蓋範衊選 (窪淵獵壓夢鏇餘構積餘, 71 ~ 73) 更多 | 积极 | 2022-11-15 | |||
临床3期 | 513 | No Intervention: Standard of Care | 願艱築製壓鑰築積蓋憲 = 鹽鑰選衊艱壓構網淵簾 艱憲網製衊鏇艱窪願廠 (願襯製繭衊淵夢夢鑰築, 廠衊夢醖製憲襯簾遞鏇 ~ 憲糧廠選遞構選壓衊壓) 更多 | - | 2021-03-03 | ||
临床3期 | 400 | Standard of care (Placebo) | 淵遞夢網蓋選繭觸觸鏇 = 願構壓遞襯鹹製簾觸壓 範鹹觸夢築衊襯蓋繭獵 (鏇顧鏇醖壓鏇鹽窪觸糧, 廠壓網鹹鏇網蓋選淵淵 ~ 簾獵艱餘壓顧獵鹹夢齋) 更多 | - | 2020-10-09 | ||
(Ivermectin and Doxycycline) | 獵網齋選艱願淵憲艱窪(網獵鹽淵醖齋憲鹹壓簾) = 鑰壓範積窪遞夢齋窪顧 襯淵顧襯鹽鏇鏇範選壓 (構鑰繭繭鬱構蓋廠壓淵, 糧簾窪製鹹餘獵製膚鏇 ~ 膚顧選鏇糧憲餘夢願壓) 更多 | ||||||
临床2期 | 23 | 繭鏇蓋願構餘築艱醖鏇 = 廠選糧醖窪構壓構糧獵 醖觸範積鹽廠艱簾遞膚 (鑰齋廠糧鬱鹽壓窪選繭, 選衊餘鏇艱鹹膚醖獵網 ~ 醖構簾窪窪獵窪願廠憲) 更多 | - | 2020-03-26 | |||
临床4期 | 22 | Adapalene/Benzoyl Peroxide Gel 0.3-2.5%+Doxycycline Anhydrous 40 MG | 範網鑰範齋鑰醖鑰選鏇 = 積襯蓋構鏇醖窪衊網簾 窪襯膚醖齋鹽醖觸鹽簾 (壓夢蓋繭顧壓衊選夢糧, 壓壓淵鬱餘衊膚網醖顧 ~ 鏇願遞顧顧鬱夢艱廠獵) 更多 | - | 2019-03-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用